imatinib has been researched along with melagatran in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Marais, A; Metternich, R; Michaelis, S; Schaudt, C; Schrey, AK; Sefkow, M | 1 |
3 other study(ies) available for imatinib and melagatran
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enzyme Inhibitors; Hep G2 Cells; Humans; K562 Cells; Mass Spectrometry; Models, Chemical; Protein Binding; Proteomics; Pyridines; Quinone Reductases; Thrombin | 2012 |